Lic Rodrigo Ojeda Salamanca1, Lic Cristopher Campos Cifuentes1 and Mg Hugo Berríos Arvey2*
1School of Medical Technology, San Sebastián University, Chile
2School of Medical Technology, Mayor University, Chile
*Corresponding Author: Mg Hugo Berríos Arvey, School of Medical Technology, Mayor University, Chile.
Received: December 28, 2021; Published: February 23, 2022
Aim: To compare the evidence of primary studies on the effectiveness of hyperbaric oxygen therapy and Bevacizumab in patients with retinal vascular obstructions.
Materials and methods: A systematic review was carried out without meta-analysis of 123 primary studies, 98 of which were excluded due to exclusion criteria, the remaining 25 studies were submitted to internal and external validity criteria, leaving 20 for research use.
Results: No significant differences were observed between the efficacy of hyperbaric oxygen therapy and Bevacizumab (0.73 and 0.78), respectively. In contrast, the cost of both benefits had a significant variation between both therapies ($20.70 and $475.42 dollars approximately).
Conclusions: Although both therapies have demonstrated efficacy in retinal vascular obstructions, the cost per individual benefit makes hyperbaric oxygen therapy more convenient and at the same time less invasive than other ophthalmologic treatments indicated for these pathologies.
Keywords: Hyperbaric Oxygen Therapy; Bevacizumab; Retinal Vascular Obstruction; Hyperbaric Chamber; RVCO; CRAO
Citation: Mg Hugo Berríos Arvey., et al. “Comparative Effectiveness of Hyperbaric Oxygen Therapy Versus Bevacizumab Therapy in Patients with Vascular Obstructions of the Retina".Acta Scientific Ophthalmology 5.3 (2022): 43-47.
Copyright: © 2022 Mg Hugo Berríos Arvey., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.